Enliven reports Q2 net loss $25.3M; positive ELVN-001 Phase 1 data with 47% MMR rate

Enliven Therapeutics, Inc.

2025-Q2 EPS reported -$1.05

Phase 1 trial of ELVN-001 in CML: 47% cumulative MMR rate; 32% achieved MMR by 24 weeks, favorable safety.
Cash, cash equivalents and marketable securities $490.5M as of June 30, 2025; cash runway into first half of 2029.
Net loss of $25.3M for Q2 2025 vs $20.0M in Q2 2024; R&D expenses $21.5M, G&A $7.1M.
Company plans to initiate Phase 3 pivotal trial of ELVN-001 in 2026.
Recent public offering generated $230M gross proceeds, strengthening balance sheet.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.